Effect of Sancao Lichang Decoction in the treatment of diarrhea irritable bowel syndrome based on TLR4/MyD88/NF-?B signaling pathway

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043689

Enrollment

Unknown

Registered

2021-02-27

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel syndrome

Interventions

Trial group:Western medicine combined with Sancao Lichang Decoction

control group:Pinaverium bromide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. It complies with the diagnostic criteria of Western medicine and the diagnosis criteria of TCM syndrome; 2, Age between 18 and 60, gender is not limited; 3. Have normal communication skills and sign informed consent.

Exclusion criteria

Exclusion criteria: Diarrhea caused by other organic diseases; The syndrome of traditional Chinese medicine is spleen-kidney Yang deficiency and cold drink stops; Patients with severe cardiovascular and cerebrovascular diseases, respiratory diseases and other diseases and unstable conditions; Organic lesions of the digestive tract, or systemic diseases affecting digestive tract motility; Pregnant and lactating women; Other uncontrolled conditions affect the treatment of the trial.

Design outcomes

Primary

Measure	Time frame
TCM symptom score;TLR4/MyD88/NF-?B signaling pathway indicators;TNF-a, IL-6;	—

Countries

China

Contacts

Public ContactZhang peng

Xuzhou Central Hospital

lsfzywww@qq.com+86 18952171694

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026